Heart drug developer Atrium Therapeutics' Q2 loss widens as expenses rise

Atrium Therapeutics

13/08/2026 22:46

Overview
U.S. biopharmaceutical firm's Q2 collaboration revenue fell yr/yr as R&D services declined
Company posted wider net loss in Q2, driven by higher R&D and G&A expenses

Outlook
Company says cash resources are sufficient to fund operations through mid-2028

Result Drivers
R&D SPENDING - Higher R&D expenses driven by clinical trial preparations and IND-enabling activities for ATR 1072
REVENUE DECLINE - Collaboration revenue fell, primarily related to R&D services under agreement with Bristol Myers Squibb
G&A COSTS - Increased general and administrative expenses due to employee-related costs, professional fees, and support for expanded operations

Company press release: ID:nPn5Cvbt9a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Basic Share
 
$1.18
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Atrium Therapeutics Inc is $25.00, about 105.4% above its August 12 closing price of $12.17

Reuters Recommended Reads
Aug 13 - Ensysce Biosciences Q2 net loss widens on higher R&D costs
Aug 13 - Lawsuit against Bristol Myers over delayed cancer drug is revived
Aug 13 - Kodiak Sciences Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)